Dermatology specialist Galderma has FDA approval for prurigo nodularis treatment Nemluvio, one of two new drugs that it thinks will deliver blockbuster sales. Dupixent nears EU approval for rare ...

Prurigo nodularis (PN) is a chronic (long-term) skin condition that causes intense itching and firm bumps on the outer layer ...

The substantial correlation between prurigo nodularis (PN) and atopic dermatitis (AD) has been highlighted by a recent ...

The Florida Entomologist, Vol. 87, No. 3 (Sep., 2004), pp. 278-282 (5 pages) The final instars of Eurytoma nodularis and E. heriadi are described and illustrated. Morphological structures of ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no ...

Explore the potential of Celldex's Barzolvolimab in Phase 3 for CSU, with strong efficacy but safety concerns, promising ...

Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising the hope of a new treatment option for the rare and highly debilitating skin ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

Considering taking supplements to treat prurigo nodularis? Below is a list of common natural remedies used to treat or reduce the symptoms of prurigo nodularis. Follow the links to read common ...

In a report released yesterday, David Lebowitz from Citi maintained a Buy rating on Celldex (CLDX – Research Report), with a price target ...

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports third-quarter ...